image_pdfimage_print

Zenyatta – Lakehead University Scientists have Successfully Produced Functionalised Graphene Oxide

Zenyatta Ventures {TSXV: ZEN} is pleased to announce that a team of scientists under the direction of Dr. Aicheng Chen at Lakehead University (‘Lakehead’) in Thunder Bay, Ontario, Canada, has made significant advancements related to sensing application development with the first graphene oxide (GO) invention produced from the Company’s high-purity Albany graphite. Continue reading

Inovio Reports New Positive Clinical Data on Advances in the Fight Against Emerging Infectious Diseases

Inovio Pharmaceuticals, Inc. {NASDAQ: INO} announced that Dr. David B. Weiner, Inovio’s co-founder, presented positive clinical data on Inovio’s DNA-based vaccines against MERS (Middle East Respiratory Syndrome) (GLS-5300) and Zika (GLS-5700) at the Coalition for Epidemic Preparedness Innovation (CEPI)’s 1st Scientific Meeting on “Vaccines Against Emerging Infections – A Global Insurance” in Paris, France. Continue reading

Radisson intersects 5.0 g/t gold over 6.0 m outside current resources, expands drill program at O’Brien

Radisson Mining Resources Inc. {TSX.V: RDS} is pleased to provide an update on the exploration program at it’s 100% owned O’Brien gold project located in the heart of the Cadillac mining camp along the Larder Lake-Cadillac fault in Quebec, Canada.

Since the last update on December 5th, 2016, assay results have been
received for three holes. Continue reading

Minera IRl release final 2016 drill results

Minera IRL Limited {CSE: MIRL} announced the final assay results of its 2016 Minapampa Far East drill program, at its Ollachea flagship gold project in Puno, Southern Peru.

The results have demonstrated that gold mineralisation at Minapampa continues over 500m to the east and remains open to the east and at depth. The results announced today are from 5,421 m (23 drill holes) of drilling conducted in 2016 at Ollachea. Continue reading

Inovio and ApolloBio to Collaborate on Development of HPV Pre-cancer Immunotherapy

Inovio Pharmaceuticals, Inc. {NASDAQ: INO} today announced that it has entered into a collaboration and license agreement providing ApolloBio Corporation (NEEQ: 430187) with the exclusive right to develop and commercialise VGX-3100, Inovio’s DNA immunotherapy product designed to treat pre-cancers caused by human papillomavirus (HPV), within Greater China (China, Hong Kong, Macao, Taiwan). Continue reading